Compare SLND & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLND | NTHI |
|---|---|---|
| Founded | 1900 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.6M | 195.5M |
| IPO Year | N/A | N/A |
| Metric | SLND | NTHI |
|---|---|---|
| Price | $3.40 | $9.52 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 46.8K | ★ 65.4K |
| Earning Date | 03-03-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $935,461,000.00 | $59,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.96 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.68 | $3.20 |
| 52 Week High | $5.34 | $25.00 |
| Indicator | SLND | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 55.54 |
| Support Level | $3.25 | $8.11 |
| Resistance Level | $3.36 | $10.19 |
| Average True Range (ATR) | 0.17 | 0.80 |
| MACD | 0.02 | 0.16 |
| Stochastic Oscillator | 72.37 | 61.98 |
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures. The company operates in two distinct segments: Civil and Transportation. The civil segment operates throughout North America and specializes in services that include the design and construction of water pipelines, pump stations, lift stations, water and wastewater treatment plants, concrete and structural steel, outfall, and tunneling. The transportation segment operates throughout North America and specializes in services that include the design and construction of bridges, roadways, marine, dredging, ship terminals and piers, and specialty structures and facilities.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).